La Roche-Posay went on official sale in India in November 2025, and it arrived carrying the loudest sentence on the pharmacy shelf: No. 1 dermatologist recommended brand worldwide. Most brands print a line like that and leave it bare. This one carries a footnote, and the footnote names a research house, a survey window and a country count. That deserves crediting. It also deserves reading closely, because the number the footnote is meant to support is given two different ways on the owner’s own pages.
La Roche-Posay is French, made in the town it is named after, and imported into India by L’Oréal’s own Indian company. That shows in the price. The 50 ml Anthelios UVMune 400 sunscreen is ₹1,400 here against €18.40 — about ₹2,035 — on the brand’s French site, roughly 31% less, both checked 4 September 2026. The dermatologist claim rests on a named 2021 survey across 34 countries, which is more working than most of this shelf shows.
Snapshot
- Founded
- 1975, by the pharmacist René Levayer, at La Roche-Posay in Vienne, France
- Current owner
- L’Oréal S.A.; trade press dates the purchase to 1989
- Indian company
- L’Oréal India Private Limited, CIN U85190MH1991PTC060363, incorporated 19 February 1991
- India launch
- November 2025, through dermatologist clinics, Nykaa, Apollo 24X7 and pharmacies
- Made where
- France — the 50 ml Anthelios declaration names the brand’s own site at 86270 La Roche-Posay
- Importer of record
- L’Oréal India Pvt Ltd, Lower Parel, Mumbai, on that declaration
- Indian price band
- ₹450 to ₹3,300 across fifteen listings, checked 4 September 2026
- Sits inside
- L’Oréal’s Dermatological Beauty division, €7,204.1 million of sales in 2025
How it started
There are four dates in this brand’s story and they are four different events, not four versions of one. The thermal centre at La Roche-Posay opened in 1905, and the brand’s own history page says it has since received over 450,000 patients for skin conditions. The laboratory itself is much younger.
- 1905The thermal centre opens at La Roche-Posay, Vienne
- 1928Trade press dates the first dermal products made with the spring water
- 1975La Roche-Posay Laboratoire Dermatologique founded by René Levayer, a pharmacist
- 1989Bought by L’Oréal, per trade press; no group release was found
- Nov 2025Official India launch, four ranges
L’Oréal’s 2025 annual report marks “50 years” for the brand, which fits the 1975 date.
The brand also tells an older story — the knight Bertrand Du Guesclin and his horse finding the springs, and on its American site, beginnings tracing back to the 1400s with “a real clinical impact for well over six centuries”. Read that as a brand legend told by the brand. No clinical evidence from the 1400s exists.
The part a buyer can actually check does hold up. The declaration on the Indian pack names the maker as La Roche-Posay Laboratoire Dermatologique, CAI 86270 La Roche-Posay, France. 86270 is the postcode of the town. The brand is made where its name says it is made, which is rarer than the marketing of French skincare suggests.
What they actually make
India got four ranges at launch, out of a French catalogue several times larger. Anthelios is the sunscreen line and the hero. Effaclar handles oily and acne-prone skin, Cicaplast is the Baume B5+ balm, and Mela B3 is the pigmentation range built around a molecule called Melasyl. Toleriane, Lipikar, Kerium and Hyalu B5 are on the French site and largely not here.
The ingredient list for the 50 ml Anthelios UVMune 400 Invisible Fluid, published on the French site and read on 4 September 2026, tells you three things the front of the bottle does not. Mexoryl 400 is the marketing name for methoxypropylamino cyclohexenylidene ethoxyethylcyanoacetate, thirteenth of twenty-four ingredients, and two older L’Oréal filters — Mexoryl SX and Mexoryl XL — sit in the same list. Alcohol denat. is the second ingredient and parfum is present, on a product sold for sensitive skin. And there is no thermal spring water entry in that list at all. The water is a brand proposition, not a universal ingredient, and the ingredient list on any pack will tell you which products carry it.
One genuine India-versus-America point sits here. The American Anthelios range, read the same day, sells Mineral Tinted, AOX Antioxidant Serum, UVAir SPF 50, Ultra Light Fluid SPF 60 and Melt-In Milk — and no UVMune 400 product at all. The United States regulates sunscreen as an over-the-counter drug with a narrower approved-filter list than Europe’s, and Mexoryl has been in and out of that process since at least 2004. The Indian buyer gets the European formula. The American buyer cannot buy it.
The Indian listings also carry a PA grade — SPF 50+ PA++++ — where the French page uses the European UVA-in-a-circle mark and no PA at all. PA is the Japanese-origin scale for UVA protection used across Asia, and it is what an Indian shopper looks for on a box.
What is published behind the SPF number is thinner than the number suggests. The French product page states the product was tested under dermatological and ophthalmic control on more than 100 people of different phototypes — that is a tolerance panel, not an SPF determination. No page read, French, Indian, international or American, names the SPF test method, the standard it followed, the laboratory that ran it, or how PA++++ was arrived at for the Indian pack. La Roche-Posay publishes the number and the grade. It does not publish the test.
What La Roche-Posay costs in India
This is where the audit turns, because the answer is the opposite of what most people expect from imported French skincare.
- France, brand’s own site, 50 ml
- €18.40 — about ₹2,035, ₹40.71 a ml
- India, MRP, 50 ml
- ₹1,400 — ₹28.00 a ml
- Gap
- 31% cheaper in India
- Checked on
- 4 September 2026
Same product, same 50 ml bottle, made in France and shipped here. The conversion uses ₹110.62 to the euro, from the US Federal Reserve’s H.10 release of 31 August 2026. French pharmacies discount hard: Citypharma in Paris was selling the same bottle at €13.48 on the day, and against that street price Apollo Pharmacy’s ₹1,288 is about 86%. Even measured against a Paris discounter, India is the cheaper counter.
Neither company page explains the difference, and European pharmacy prices carry their own taxes, margins and competitive set, so treat this as a like-for-like on two shelves rather than an explanation of either. What is on the record is who brings it in. The importer named on the declaration is L’Oréal India Pvt Ltd — the owner’s own Indian company, not a third-party distributor with a margin of its own to take.
The per-millilitre ladder is where the real decision lives.
| Product and size | Indian price | Per ml |
|---|---|---|
| Effaclar Purifying Foaming Gel, 200 ml | ₹1,400 | ₹7.00 |
| Mela B3 Facial Gel Cleanser, 200 ml | ₹1,450 | ₹7.25 |
| Anthelios UVMune 400 Invisible Fluid, 50 ml | ₹1,400 | ₹28.00 |
| Cicaplast Baume B5+, 40 ml | ₹1,150 | ₹28.75 |
| Effaclar Duo+M Gel Cream, 40 ml | ₹1,250 | ₹31.25 |
| Anthelios UVMune 400 Invisible Fluid, 15 ml | ₹599 | ₹39.93 |
| Effaclar Duo+M Gel Cream, 7.5 ml | ₹450 | ₹60.00 |
| Mela B3 Face Serum, 30 ml | ₹3,300 | ₹110.00 |
| Mela B3 Anti-Dark Spot Serum, 10 ml | ₹1,250 | ₹125.00 |
Apollo Pharmacy brand page, cross-checked against Nykaa and Clinikally, all read 4 September 2026. MRP where shown, selling price otherwise.
Do the arithmetic and the small bottles look different. The 15 ml sunscreen costs 43% more per millilitre than the 50 ml. The 7.5 ml Effaclar Duo+M costs 92% more per millilitre than the 40 ml. Those ₹450 and ₹599 tickets are how a ₹1,400 brand gets on to a pharmacy shelf an Indian shopper will reach for, and they are the worst value in the range. Buy them once to test the product on your skin, then buy the big one.
An MRP a shop knocks 8% off is the ordinary Indian arrangement, and it is the same arithmetic we work through on a different shelf in our Liberty pages. The marketer-and-manufacturer question is worth asking of every brand and the answers vary more than the packaging admits: Campus runs its own factories, and Bata India is a listed Indian company distinct from the brand it sells. La Roche-Posay is a third arrangement — a French plant owned by the group, with the group’s own Indian arm as importer and packer.
A survey from 2021 is doing the work of a sentence printed in 2026.
Who La Roche-Posay is actually for
This is a brand for someone who wants a European sunscreen filter set with a PA grade on the box, or a pigmentation routine, and who is comfortable paying between ₹1,150 and ₹1,500 for a single item. Below that ticket the shelf is crowded with Indian and Korean options. Above it, the Mela B3 serum at ₹3,300 for 30 ml sits with the priciest things in the category.
Two lines on the pack deserve reading before you buy. Alcohol denat. is second on the Anthelios ingredient list and parfum is present, which matters if fragrance or drying alcohols are the reason you left your last sunscreen. The brand’s own answer is the tolerance panel of more than 100 people it cites on the French page; that is the evidence it publishes, and it is about tolerance rather than efficacy.
The Indian Amazon listing also carries the line “Also suitable for patients undergoing cancer treatment.” The brand does run a documented oncology-support programme — L’Oréal’s group page cites more than a million people supported since 2021, and the Union for International Cancer Control lists the brand as a partner. We are reporting that the listing says it and that the programme exists. Nothing on this page is medical advice, and anyone in treatment should take that question to their oncologist rather than to a listing.
At the November 2025 launch, the dermatologist Dr Jaishree Sharad was quoted in the press release saying the Mela B3 serum is “clinically proven to reduce up to 90% cases of persistent dark spots”. That is a quotation from a launch release. No study, panel size, duration or endpoint for the 90% figure appears on any page read.
Reputation and controversies
Start with what the brand publishes, because it publishes more than most of this shelf. The claim “No. 1 dermatologist recommended brand worldwide” carries a footnote on both the international and the Indian site, in identical words: “Survey conducted among the dermocosmetic market carried out by AplusA and other partners between January 2021 and July 2021, involving dermatologists in 34 countries, representing more than 82% of the worldwide GDP.” AplusA is a French healthcare market-research firm. A named house, a named window and a named scope is real substantiation, and it should be credited as such.
What the footnote states is also what it bounds. It does not give the number of dermatologists surveyed, how they were sampled, what question was put, or what “recommended” meant on the questionnaire. It measures what dermatologists said they recommend, which is a market-research finding rather than a clinical one. The window closed in July 2021 and the claim is being printed in 2026; whether the survey has been repeated is not stated on any page read.
Then there are the numbers themselves, and the honest thing is to set them beside each other. On 4 September 2026 the brand’s American site said “recommended by 90,000 dermatologists worldwide”, and the Union for International Cancer Control’s partner page carried the same figure. On the same day L’Oréal’s group site said “recommended by more than 100,000 dermatologists worldwide”, with a stat block reading 100k. Both pages belong to the same owner. No page read explains how either count was arrived at.
The clinical-study count runs the same way across three pages of the same owner, all read on 4 September 2026: “nearly 600 clinical studies” on the Singapore site, “over 750+ studies” on the American site, “+800 clinical studies” on loreal.com. The Singapore page is the only one that defines the term, and its definition is the useful part: “a test conducted on volonteers under dermatological control to demonstrate La Roche-Posay products’ benefits on different skin issues under use conditions that are close to real life” — the spelling is the brand’s. That describes a product-in-use test under dermatological supervision. It is not the same thing as a randomised controlled trial, and the word “clinical” carries both.
None of that is a product finding. It is a disclosure observation about how figures are published across a group’s own websites, and a reader can check every one of them.
On the regulatory record, three spellings of the brand name and the parent’s Indian entity were searched on the advertising council’s published complaint outcomes on 4 September 2026, and no outcome naming La Roche-Posay was found. The council is a self-regulatory industry body rather than a statutory regulator, its published file is not a complete map of every complaint ever made, and nobody has ruled on the pages as they read today. So the dermatologist claim, the SPF 50+ PA++++ claim and the cancer-treatment line all sit untested by it. Untested is not approved, in either direction.
A search of Indian Kanoon, the public database of Indian judgments, on 4 September 2026 found no decision naming La Roche-Posay. That database does not index every consumer commission and tribunal, so read it as a narrow finding rather than a clean bill.
Animal testing is the one place where the brand’s owner and its loudest critic both have statements on the record. L’Oréal says: “Since 1989, we have not tested the safety of our products on animals, 14 years before regulations required us to do so.” PETA’s Beauty Without Bunnies directory lists L’Oréal USA under Companies to Avoid. There is no brand-level entry for La Roche-Posay in that directory, so no brand status can be quoted either way. Testing cosmetics on animals has been illegal in India since 2014, so the disagreement concerns other markets. One point in the brand’s favour: La Roche-Posay makes no cruelty-free claim on any page read, so there is no badge here to check.
Buying it in India
Almost everything above can be settled in a shop, on the box, in about a minute. Imported cosmetics fall under the Drugs and Cosmetics Act 1940 and the Cosmetics Rules 2020, which require registration with the central drug authority before import, and require the pack to carry the registration certificate number, the certificate holder, and the actual manufacturer’s name and premises.
Read the declaration block
On the 50 ml Anthelios it reads: country of origin France; manufacturer La Roche-Posay Laboratoire Dermatologique, CAI 86270 La Roche-Posay; importer and packer L’Oréal India Pvt Ltd, Mumbai. Ask a seller to show you those lines on whatever you are actually buying.
Ask for the import registration number
An imported cosmetic needs a registration certificate, and its number belongs on the pack — Avène’s Indian pack prints RC/COS-003873. The register itself is not open to the public, so the number on the box is the handle you have.
Ignore the origin dropdown, read the free text
Marketplace listings carry a tidy “country of origin” field that is filled in by the seller and is often wrong. Only the free-text declaration block, the one with the manufacturer’s address in it, is the statutory one.
Work out the price per millilitre
Divide the price by the net quantity on the pack. ₹1,400 over 50 ml is ₹28.00; ₹599 over 15 ml is ₹39.93. The trial size costs 43% more per millilitre than the bottle beside it.
Find the filters and the alcohol yourself
On the Anthelios list, alcohol denat. is second and parfum is last. Mexoryl 400 appears under its chemical name, methoxypropylamino cyclohexenylidene ethoxyethylcyanoacetate. The list is on the carton, in that order, by law.
The declaration quoted here covers one bottle, the 50 ml Anthelios. Origin, manufacturer and importer are printed on every pack sold here, so read them on the product you are actually picking up rather than assuming the range is uniform.
Common questions
Is La Roche-Posay actually made in France?
The 50 ml Anthelios UVMune 400 sold in India declares country of origin France, and names the maker as La Roche-Posay Laboratoire Dermatologique at CAI 86270 La Roche-Posay — the postcode of the town the brand is named after. That covers one product. Check the declaration on whichever pack you buy.
Is it cheaper in India than in Europe?
On the one product measured, yes. The 50 ml Anthelios is ₹1,400 in India against €18.40, about ₹2,035, on the brand’s French site — roughly 31% less, both checked 4 September 2026. Against a heavily discounting Paris pharmacy at €13.48, the Indian selling price of ₹1,288 is about 86%.
Who owns La Roche-Posay, and who sells it in India?
L’Oréal S.A. owns it; trade press dates the purchase to 1989. In India it is handled by L’Oréal India Private Limited, CIN U85190MH1991PTC060363, which is also the importer and packer named on the Anthelios declaration and which runs 26 L’Oréal brands here.
What is behind the “No. 1 dermatologist recommended” line?
A footnote on the brand’s international and Indian sites cites a survey by AplusA and partners, run between January and July 2021, covering dermatologists in 34 countries. It does not say how many dermatologists were asked or what question was put. The count the claim travels with appears as 90,000 on the brand’s American site and as more than 100,000 on L’Oréal’s group site.
Has the SPF 50+ PA++++ rating been independently verified?
No page read publishes the SPF test method, the standard, the laboratory or the report, and none explains how PA++++ was determined for the Indian pack. The “more than 100 people” figure on the French page belongs to a tolerance test under dermatological and ophthalmic control, not to the SPF determination.
Is La Roche-Posay the same thing as CeraVe?
Same parent and the same Indian company, and opposite supply chains. The Anthelios sunscreen declares France. CeraVe’s Moisturising Cream sold here declares India, made at Chakan near Pune under cosmetic licence M MH/105568.
How we research and verify brand audits: our methodology.
References
- La Roche-Posay international site, read 4 September 2026 — the AplusA footnote to the dermatologist claim
- La Roche-Posay India site, read 4 September 2026 — the same footnote in identical words on the Indian site
- La Roche-Posay, The History of La Roche-Posay, read 4 September 2026 — 1905 thermal centre, 450,000 patients, 1975 founding by René Levayer
- Cosmetics Business, Something in the water for La Roche-Posay — the 1928 date and the 1989 acquisition by L’Oréal
- L’Oréal Annual Report 2025, Dermatological Beauty — division sales of €7,204.1 million, and 50 years of the brand
- MediaBrief, 7 November 2025 — the India launch, the four ranges, the channels and the Mela B3 quotation
- Amazon India, Anthelios UVMune 400 Invisible Fluid SPF50+ 50 ml, read 4 September 2026 — the declaration block, the PA++++ grade and the cancer-treatment line
- La Roche-Posay France, Anthelios UVMune 400 product page, read 4 September 2026 — the €18.40 list price, the full ingredient list and the tolerance panel
- La Roche-Posay US, Anthelios range, read 4 September 2026 — the American range as listed, with no UVMune 400 product
- La Roche-Posay US, Our Story, read 4 September 2026 — 90,000 dermatologists, “over 750+ studies”, the 1400s origin story
- L’Oréal, La Roche-Posay brand page, read 4 September 2026 — more than 100,000 dermatologists, +800 clinical studies, the cancer-support figure
- La Roche-Posay Singapore, commitment to science-backed dermatology, read 4 September 2026 — “nearly 600 clinical studies” and the definition of the term
- Union for International Cancer Control, La Roche-Posay partner page — the 90,000 figure and the oncology partnership
- Apollo Pharmacy, La Roche-Posay brand page, read 4 September 2026 — Indian MRPs and selling prices for the whole ladder
- Pharmacie Citypharma, Paris, read 4 September 2026 — the €13.48 French street price
- US Federal Reserve H.10, released 31 August 2026 — the euro and dollar rates used for every conversion here
- CDSCO, Registration and Import of Cosmetics into India, 19 January 2021 — the registration requirement and what the pack must carry
- PETA Beauty Without Bunnies, L’Oreal USA — the Companies to Avoid listing for the parent
- L’Oréal, For Beauty With No Animal Testing — the company’s own statement, quoted in full above
On the two things this site cares about most, La Roche-Posay does well. It is made where it says it is made, at the brand’s own site in the town it is named after, and it is brought in by its owner’s own Indian company rather than a third party. A French-made bottle costs ₹1,400 here against ₹2,035 on the brand’s French site. If you want a European filter set with a PA grade on the box, the 50 ml Anthelios at ₹28.00 a millilitre is a fair deal by Indian pharmacy standards.
The claims are a different story, and it is a story about disclosure rather than about the product. The dermatologist footnote is the best published on this shelf and it is five years old and silent on sample size. The count it travels with is 90,000 on one of the owner’s sites and more than 100,000 on another. The study count is 600, 750-plus and 800 across three more. And on the one claim that actually determines whether you burn — SPF 50+ PA++++ — the number is printed and the test behind it is not. Skip the ₹450 and ₹599 trial sizes; at ₹60.00 and ₹39.93 a millilitre they are the worst arithmetic in the range.
Buy it for the filter set and the declaration on the box; the number on the front is the least settled thing about it.
